Bristol-Myers Squibb Company (BMY) Stock
BMY Key Statistics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
CEO: Christopher Boerner. Company website
BMY — Frequently Asked Questions
What is the BMY stock price today?
Bristol-Myers Squibb Company (BMY) trades at $63.06, up 0.35% on the day, as of Sep 20, 2026 13:07 UTC.
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company has a market capitalisation of $128.81B, calculated from the live BMY share price and shares outstanding.
What is the P/E ratio of BMY?
BMY trades at a trailing P/E of 13.89, from earnings per share of $4.54 over the last twelve months.
How much revenue does Bristol-Myers Squibb Company make?
Bristol-Myers Squibb Company generated revenue of $49.19B over the trailing twelve months, which puts the stock at 2.62 times sales.
Does BMY pay a dividend?
Yes. Bristol-Myers Squibb Company pays a dividend yielding 4.44% on the current share price.
What is the 52-week range for BMY?
BMY has traded between $42.59 and $68.64 over the past 52 weeks, and the last price is 8.1% below that high.
Is Bristol-Myers Squibb Company profitable?
Yes. Bristol-Myers Squibb Company keeps 18.87% of revenue as net income over the trailing twelve months.
What is the analyst price target for BMY?
Wall Street analysts rate BMY Buy, with an average price target of $68.29, 8.3% above the current price.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in US.
Who is the CEO of Bristol-Myers Squibb Company?
Christopher Boerner is the chief executive of Bristol-Myers Squibb Company, which employs 32,500 people.
Where can I track BMY in real time?
QFI Terminal shows BMY with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See BMY live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open BMY in Terminal See plans